Abstract:Acute myeloid leukemia (AML) is an aggressive haematological cancer characterized phenotypically by the rapid clonal growth of myeloid cells and an accumulation of immature blasts. Although major progress has been made in identifying different genetic and molecular AML subgroups, treatment and long-term patient outcomes have not changed significantly over the past four decades. Recently, venetoclax (ABT-199), a selective BCL-2 inhibitor, has been approved for the treatment of older patients with AML. However, drug resistance and disease progression on venetoclax as well as the inherent resistance of leukemic stem cells (LSCs) to therapy pose significant clinical challenges. One candidate target for improved therapies is AXL, a member of the TYRO3/AXL/MER (TAM) family of receptor tyrosine kinases that is elevated in AML cells and LSCs, and associated with poor prognosis in AML. To test whether targeting of AXL is a feasible treatment strategy for AML, in particular to eradicate LSCs, we developed a potent and selective AXL inhibitor. We show that AXL inhibition targets AML cells with high AXL expression and synergizes with venetoclax decreasing the viability of primitive AML patient cells and reducing their clonal short- and long-term colony assay outputs compared to single or control treatments. Moreover, a combination of AXL inhibition and venetoclax treatment was able to target LSCs and AML blasts in two different preclinical patient-derived xenotransplantation (PDX) models. Single-cell RNA-sequencing and functional validation studies revealed that AXL inhibition perturbs oxidative metabolism and differentially targets signaling pathways to synergize with venetoclax in leukemic cell killing. Importantly, the combination of AXL inhibition plus venetoclax was not toxic to normal BM cells from healthy donors. Hence, our findings identify a promising, improved and specific treatment strategy for AML. Acute myeloid leukemia (AML) is an aggressive haematological cancer characterized phenotypically by the rapid clonal growth of myeloid cells and an accumulation of immature blasts. Although major progress has been made in identifying different genetic and molecular AML subgroups, treatment and long-term patient outcomes have not changed significantly over the past four decades. Recently, venetoclax (ABT-199), a selective BCL-2 inhibitor, has been approved for the treatment of older patients with AML. However, drug resistance and disease progression on venetoclax as well as the inherent resistance of leukemic stem cells (LSCs) to therapy pose significant clinical challenges. One candidate target for improved therapies is AXL, a member of the TYRO3/AXL/MER (TAM) family of receptor tyrosine kinases that is elevated in AML cells and LSCs, and associated with poor prognosis in AML. To test whether targeting of AXL is a feasible treatment strategy for AML, in particular to eradicate LSCs, we developed a potent and selective AXL inhibitor. We show that AXL inhibition targets AML cells with high AXL expression and synergizes with venetoclax decreasing the viability of primitive AML patient cells and reducing their clonal short- and long-term colony assay outputs compared to single or control treatments. Moreover, a combination of AXL inhibition and venetoclax treatment was able to target LSCs and AML blasts in two different preclinical patient-derived xenotransplantation (PDX) models. Single-cell RNA-sequencing and functional validation studies revealed that AXL inhibition perturbs oxidative metabolism and differentially targets signaling pathways to synergize with venetoclax in leukemic cell killing. Importantly, the combination of AXL inhibition plus venetoclax was not toxic to normal BM cells from healthy donors. Hence, our findings identify a promising, improved and specific treatment strategy for AML.

Abstract A01: Development of a novel BTK inhibitor against resistant acute myeloid leukemia

Abivertinib Synergistically Strengthens the Anti‐leukemia Activity of Venetoclax in Acute Myeloid Leukemia in a BTK‐dependent Manner

Abstract 4004: Targeting drug-resistant acute myeloid leukemia (AML) cells using novel casein kinase II (CK2) inhibitor

Abstract A04: Targeted protein degradation as a strategy to overcome non-covalent BTK inhibitor resistance in lymphoma

Abstract 605: ABBV-101, a highly potent and selective clinical stage Bruton tyrosine kinase degrader, overcomes BTK mutation-induced resistance to BTK inhibitors

Abstract 4725: the Epigenetic Determinants of BTKi Efficacy in Chronic Lymphocytic Leukemia

Abstract 5718: TGN-1062, a dual CDK7 and FLT3 Inhibitor, shows potent anti-AML activity and synergizes with Venetoclax

Abstract 380: BaF3-BTK engineering cell lines as a useful platform for novel BTK inhibitor discovery

Abstract 6069: Discovery and preclinical development of orally bioavailable potent BTK degrader, and its early clinical development for the treatment of relapsed and refractory B-cell malignancies

Abstract 4670: KS18, an Mcl-1 inhibitor, triggers cell death and enhances the therapeutic efficacy of venetoclax in bortezomib-resistant multiple myeloma cells

Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127

Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL)

Abstract 3451: XS-04: A first-in-class dual IRAK4/BTK inhibitor for the treatment of hematological malignancies

Abstract 5438: FCN-589, a novel, potent and selective BTK inhibitor, targets BTK C481S for the treatment of B-cell malignancies

Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia.

Discovery of a BTK/MNK Dual Inhibitor for Lymphoma and Leukemia.

3125 – COMBINING VENETOCLAX TREATMENT WITH AXL KINASE INHIBITION TARGETS CANCER STEM AND PROGENITOR CELLS IN ACUTE MYELOID LEUKEMIA

Abstract 4669: Differential preclinical activity of Bruton tyrosine kinase inhibitors (BTKis) against BTK resistance-associated mutations

Clinical Characteristics, Treatment Strategies, and Outcomes for CLL Patients with BTK Mutation; A Single Center Study

Abstract 7218: Venetoclax triggers apoptosis and augments the effectiveness of doxorubicin against acute myeloid leukemia cells

Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia